Early‐phase clinical trials as well as observational studies also suggest potential benefits of GLP‐1 RAs in people with Alzheimer's disease and those with Parkinson's disease (due to potential neuroprotective effects of GLP‐1 RAs) [21, 22, 23], when retrospective observational data suggest that GLP‐1 RAs may also reduce the risk for certain obesity‐related cancers such as colorectal, pancreatic and breast cancer [24]. This evidence concerns the gene GCG and Parkinson disease.